New
Pune-based startup Ahammune Biosciences has recently completed the phase 1 clinical trials of its investigational new drug AB1001, being developed as a topical therapy for vitiligo.
Dr T. Balganesh, Chairman of Ahammune’s Board said, “Vitiligo is a much neglected disease and specific treatments for the disease are not available. AB1001 is a novel class of compounds, discovered and developed at Ahammune, that has the potential to not only limit the progression of the disease but also reverses the pigmentation loss. The successful completion of Phase 1 of the molecule brings a much wanted treatment closer to the patients. We are looking forward to the compound becoming a drug shortly.”
Ahammune Biosciences and Ahmedabad-based Veeda Clinical Research had partnered for the first in human studies with Ahammune’s investigational new drug AB1001.
FAQOther Questions
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Can Ayurveda help with vitiligo?
Vitiligo is an autoimmune condition characterized by white patches of skin that can develop and spread unpredictably. While there is no cure, medical treatments and complementar...
- I have vitiligo: will my children have vitiligo, too?
If you have vitiligo, you might wonder about the chances of your children developing the condition. While there is a genetic component, vitiligo is not a straightforward heredit...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.